Drug Profile
Research programme: gene therapies - Generation Bio
Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Generation Bio
- Class Antihaemorrhagics; Eye disorder therapies; Gene therapies; Hepatoprotectants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders; Haemophilia A; Phenylketonuria
- Research Gaucher's disease; Hepatolenticular degeneration; Liver disorders; Stargardt disease
- No development reported Inborn genetic disorders; Wet age-related macular degeneration
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Eye-disorders in USA (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in Wet age-related macular degeneration in USA (Parenteral)
- 09 Nov 2023 Pharmacodynamics data from preclinical studies released by Generation Bio